Payment overview · 2025
General Payments
$137.46
6 reported records · 6 companies
Healthcare provider profile · identity verified
Thuan H Vo, M.D.
Allopathic & Osteopathic Physicians|General Practice · WESTMINSTER, CA · NPI 1366434748
Verified facts
What the public records show
CMS Open Payments records show Thuan H Vo, M.D. received $137.46 in general payments during 2025 across 6 reported records.
Lilly USA, LLC accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.66 | 24.5% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $28.81 | 21.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.74 | 17.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.21 | 13.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $16.57 | 12.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.47 | 12.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $137.46 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $52.55 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $33.66 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 113 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 189 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 231 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
113 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
231 | 72 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
140 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
231 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
189 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1228 | 313 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1126 | 285 |
| Celecoxib | Celecoxib | 1078 | 403 |
| Losartan Potassium | Losartan Potassium | 930 | 215 |
| Amoxicillin | Amoxicillin | 792 | 425 |
| Metformin Hcl | Metformin Hcl | 699 | 163 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 547 | 226 |
| Tamsulosin Hcl | Tamsulosin Hcl | 529 | 131 |
| Omeprazole | Omeprazole | 504 | 183 |
| Gabapentin | Gabapentin | 475 | 133 |
| Baclofen | Baclofen | 450 | 196 |
| Vascepa | Icosapent Ethyl | 415 | 83 |
| Dexlansoprazole Dr | Dexlansoprazole | 379 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 351 | 94 |
| Atenolol | Atenolol | 328 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 296 | 108 |
| Famotidine | Famotidine | 295 | 107 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 286 | 81 |
| Finasteride | Finasteride | 278 | 70 |
| Lovastatin | Lovastatin | 272 | 59 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 269 | 168 |
| Benazepril Hcl | Benazepril Hcl | 263 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 72 |
| Montelukast Sodium | Montelukast Sodium | 249 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 248 | 80 |
| Diclofenac Sodium | Diclofenac Sodium | 239 | 87 |
| Megestrol Acetate | Megestrol Acetate | 238 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 94 |
| Linzess | Linaclotide | 231 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 49 |
| Doxazosin Mesylate | Doxazosin Mesylate | 214 | 52 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 206 | 103 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 198 | 60 |
| Azithromycin | Azithromycin | 196 | 122 |
| Alendronate Sodium | Alendronate Sodium | 192 | 51 |
| Fenofibrate | Fenofibrate | 189 | 45 |
| Jardiance | Empagliflozin | 189 | 31 |
| Mirtazapine | Mirtazapine | 189 | 70 |
| Meclizine Hcl | Meclizine Hcl | 184 | 86 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 52 |
| Januvia | Sitagliptin Phosphate | 165 | 33 |
| Myrbetriq | Mirabegron | 163 | 30 |
| Donepezil Hcl | Donepezil Hcl | 156 | 51 |
| Simvastatin | Simvastatin | 143 | 33 |
| Cromolyn Sodium | Cromolyn Sodium | 142 | 43 |
| Lisinopril | Lisinopril | 141 | 36 |
| Farxiga | Dapagliflozin Propanediol | 140 | 31 |
| Tradjenta | Linagliptin | 140 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 138 | 43 |
| Cyclosporine | Cyclosporine | 125 | 37 |
| Icosapent Ethyl | Icosapent Ethyl | 123 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 29 |
| Creon | Lipase/Protease/Amylase | 113 | 27 |
| Glipizide | Glipizide | 112 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 106 | 27 |
| Colchicine | Colchicine | 104 | 51 |
| Allopurinol | Allopurinol | 100 | 29 |
| Hydrocortisone | Hydrocortisone | 100 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 73 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 24 |
| Clonidine Hcl | Clonidine Hcl | 96 | 22 |
| Trazodone Hcl | Trazodone Hcl | 96 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 47 |
| Restasis | Cyclosporine | 93 | 22 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 88 | 43 |
| Lidocaine | Lidocaine | 85 | 31 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 84 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 84 | 46 |
| Carvedilol | Carvedilol | 77 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 75 | 21 |
| Pregabalin | Pregabalin | 73 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 72 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 71 | 16 |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 71 | 41 |
| Cephalexin | Cephalexin | 70 | 48 |
| Eliquis | Apixaban | 68 | 14 |
| Ezetimibe | Ezetimibe | 67 | 17 |
| Azelastine Hcl | Azelastine Hcl | 64 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 14 |
| Methimazole | Methimazole | 63 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 62 | 19 |
| Nitroglycerin | Nitroglycerin | 61 | 29 |
| Glimepiride | Glimepiride | 56 | 14 |
| Prolia | Denosumab | 56 | 33 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 46 |
| Lactulose | Lactulose | 54 | 18 |
| Procto-Med Hc | Hydrocortisone | 54 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 22 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Naproxen | Naproxen | 51 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 51 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 15 |
| Tramadol Hcl | Tramadol Hcl | 50 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 19 |
| Clotrimazole | Clotrimazole | 46 | 17 |
| Ketoconazole | Ketoconazole | 46 | 18 |
| Methocarbamol | Methocarbamol | 46 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 42 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | 11 |
| Metformin Hcl Er | Metformin Hcl | 41 | 15 |
| Valsartan | Valsartan | 39 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 38 | 15 |
| Dutasteride | Dutasteride | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Prednisone | Prednisone | 35 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 32 |
| Sucralfate | Sucralfate | 32 | 11 |
| Loperamide | Loperamide Hcl | 31 | 18 |
| Nifedipine Er | Nifedipine | 31 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 30 | 20 |
| Alprazolam | Alprazolam | 29 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 16 |
| Triazolam | Triazolam | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 28 | 25 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 28 | 18 |
| Mitigare | Colchicine | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Meloxicam | Meloxicam | 23 | 11 |
| Ondansetron Odt | Ondansetron | 23 | 18 |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Erythromycin | Erythromycin Base | 20 | 12 |
| Fluocinonide | Fluocinonide | 20 | 11 |
| Proctozone-Hc | Hydrocortisone | 20 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 19 | 11 |
| Lumigan | Bimatoprost | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 12 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Furosemide | Furosemide | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 15 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Entecavir | Entecavir | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 11 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Benzonatate | Benzonatate | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 14 | 11 |
| Haloperidol | Haloperidol | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $137.46 · 6 records | Lilly USA, LLC | BREZTRI, CREON, JARDIANCE, LINZESS, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error